For Research Use Only. Not for Human Consumption.
Recorded market$65.10Recorded exact-size market estimate: 65.10 USD for one 10 mg container (6.509700 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$65.00Member price$37.0343.1% lessMembers save $28.07 on this item vs. recorded market
Selective growth-hormone secretagogue for endocrine research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$3.70/mg43.1% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:11 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Prism Labs Oct 11, 2026 UTC | One 10 mg container; 49.99 USD | $5.00/mg | lyophilized powder; InStock Rendered screenshot explicitly shows Ipamorelin heading, vial10MG and COA card Ipamorelin10mg. Public DOM masks compound text as generic; screenshot resolves identity. Age notice unaccepted. Price observation; no COA authentication is implied by inclusion. |
| Ion Compounds Oct 11, 2026 UTC | One 10 mg container; 59.00 USD | $5.90/mg | lyophilized powder; InStock 59/vial,1vial59; UnitPriceSpecificationUSD59; BACaccessory14.99separatelypriced; Ipamorelin10MG; 1vialselected;2/3vialtiers separate; FORM LYO; Unacceptedage/researchoverlay; publicbodypricevisible Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 11, 2026 UTC | One 10 mg container; 55.00 USD | $5.50/mg | lyophilized powder; InStock Selected10mg55 estimatedtotal1product55; OfferUSD55; Amount3mlVial10mg; one3mlvial quantity1; ProductinformationFormLyophilizedPowder Price observation; no COA authentication is implied by inclusion. |
| American Bio Tech (Vector redirect) Oct 11, 2026 UTC | One 10 mg container; 49.99 USD | $5.00/mg | lyophilized powder; InStock PerVial49.99; AggregateOfferUSD49.99; 10mg; 1vial49.99; Lyophilizedpowder; vector.store redirectsamericanbio.tech countonce Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 10, 2026 UTC | One 10 mg container; 59.99 USD | $6.00/mg | powder; publicly listed Exact10mg lyophilized singlevial publicUSD59.99 Price observation; no COA authentication is implied by inclusion. |
| Island Peptides Oct 10, 2026 UTC | One 10 mg container; 78.00 USD | $7.80/mg | powder; publicly listed Exact10mg lyophilized singlevial publicUSD78 Price observation; no COA authentication is implied by inclusion. |
| Bluum Peptides Oct 11, 2026 UTC | One 10 mg container; 59.00 USD | $5.90/mg | powder; in stock Exact selected10mg Buy1 Standard59USD, public mapped ProductVariantIPA10 Offer. Productspec sealed10mg lyoph powder research vial; qty1. Basic age21+RUO notice remains unaccepted, no Terms/professional entry requirement. Price observation; no COA authentication is implied by inclusion. |
| Red Rock Peptides Oct 11, 2026 UTC | One 10 mg container; 81.00 USD | $8.10/mg | powder; in stock Explicit single-component10mg lyoph powder sealed researchvial, q1 public81USDOffer taxexcluded. Noentrygate afterstablescreenshot. Price observation; no COA authentication is implied by inclusion. |
| Orion Peptides Oct 11, 2026 UTC | One 10 mg container; 90.00 USD | $9.00/mg | powder; in stock Own description explicit eachvial10mg lyoph powder, q1 current90USDmappedOffer. Singlevial inferred eachvial/q1/photo/noindicatedkit. Bulk3/5/10tiersnotused. Openpublicafterstablescreenshot; footeraddress contains internallyinconsistent LA/NY noted unverifiedretaileridentity. Price observation; no COA authentication is implied by inclusion. |
| MitoBioLabs Oct 11, 2026 UTC | One 10 mg container; 69.00 USD | $6.90/mg | powder; public orderable Eachvial10mg lyoph powder, q1 current69USDmappedOffer. Singlevial inferred vialcontent/q1/photo/noindicatedkit. Basic age21+RUOnoticeunaccepted; qualifications/liability footer purchase-only, no entryattestation. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Ipamorelin – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/ipamorelin-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/ipamorelin-10-mg/
A pentapeptide ghrelin-receptor agonist noted for selective growth-hormone secretagogue activity in endocrine research models.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Ipamorelin is a synthetic peptide studied for growth-hormone release and gastrointestinal effects. Human research exists, but the outcome matters: a hormone response is not proof of muscle gain, and a postoperative trial did not demonstrate a significant improvement in its main efficacy comparisons.
Ipamorelin is distinct from growth hormone, GHRH and other secretagogues. A marketed combination adds another intervention whose effects cannot be inferred from a single-agent study.
The actual preparation, salt form and route should remain specified. A short intravenous trial does not authenticate or validate an unrelated subcutaneous product.
One study modeled drug exposure and growth-hormone response in healthy volunteers. A later randomized trial assessed recovery of eating after bowel surgery. Together, these show biological activity and an explored clinical use, but do not establish the broad body-composition and rejuvenation claims often associated with secretagogues.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Ipamorelin human pharmacology
Escalating-exposure study in healthy male volunteers Reading scope: PubMed abstract |
The study characterized circulating ipamorelin and a short growth-hormone-release response. | It did not measure durable muscle, fat-loss or functional outcomes. |
| Ipamorelin after bowel resection
Multicenter randomized placebo-controlled proof-of-concept trial Reading scope: PubMed abstract |
The difference in time to a tolerated meal was not statistically significant, and the reported efficacy comparisons were neutral. | The modest trial and specific hospital setting do not establish other benefits or long-term safety. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
It is inaccurate to summarize the postoperative trial simply as “improved gut recovery” without the non-significant comparison. A numerical difference between groups does not automatically demonstrate that treatment caused a benefit.
The pharmacology study answers how exposure and a hormone response related under its conditions. Its modeled parameters do not identify a clinically useful long-term schedule.
Claims that combining ipamorelin with CJC-1295 is proven safer or more effective need direct evidence for the specified combination, not a chain of single-agent mechanisms.
A meaningful research update would report a controlled patient-relevant benefit and harms together. More detailed hormone peaks alone would not establish the promised outcome.
FDA flags limited route-specific safety information and potential immunogenicity concerns for ipamorelin preparations. Brief study tolerability should not be advertised as universal safety.
The intravenous research does not provide a validated home injection or combination schedule. The formulation, delivery method and clinical purpose differ.
A reported elimination half-life describes the study’s pharmacokinetics. It should not be used alone to infer how often someone should administer a compound.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Verify ipamorelin identity, stated salt and content. For a combination, obtain separate component identification and quantities; a total blend mass cannot establish the ipamorelin amount.
Check that a seller’s cited study concerns the actual compound and outcome rather than a different secretagogue.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
The checked trial did not find significant differences in its main and secondary efficacy analyses. It was a proof-of-concept study, not definitive evidence of benefit.
No. Those are different outcomes. The pharmacology paper did not establish a durable body-composition or strength effect.
This companion to the Ipamorelin research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
The intravenous research does not provide a validated home injection or combination schedule. The formulation, delivery method and clinical purpose differ.
A reported elimination half-life describes the study’s pharmacokinetics. It should not be used alone to infer how often someone should administer a compound.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.